GLP-1 receptor agonists linked to lower medication use and reduced headaches, visual disturbances or blindness, and papilledema<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, July 21, 2025 (HealthDay News) — For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is associated with improved clinical outcomes compared with conventional therapies, according to a study published online July 14 in JAMA Neurology<\/em>.<\/p>\n Georgios S. Sioutas, M.D., from the Virginia Commonwealth University Health System in Richmond, and colleagues conducted a retrospective cohort study using data from the TriNetX U.S. Collaborative Network between 2005 and 2024. Electronic health records from 67 health care organizations were referenced to examine initiation of GLP1-RA therapy within six months of IIH diagnosis. The control group included patients managed with conventional treatments, such as acetazolamide, topiramate, and dietary counseling.<\/p>\n A total of 44,373 patients with IIH were identified; the cohort included 555 GLP-1 RA users and 555 nonusers, after propensity score matching. The researchers found that use of GLP-1 RAs was associated with lower medication use, reduced headaches, visual disturbances or blindness, and papilledema (risk ratios, 0.53, 0.45, 0.60, and 0.19, respectively). The GLP-1 RA group also had a lower risk of procedures and mortality (risk ratios, 0.44 and 0.36, respectively), but no difference was seen between the groups in mean body mass index (BMI) at follow-up. Similar associations were seen in sensitivity analysis stratified by BMI (\u226540 versus <40 kg\/m2<\/sup>). Greater weight loss was seen in association with bariatric surgery, but better outcomes were seen in association with GLP-1 RA therapy.<\/p>\n “This retrospective multicenter study suggests GLP-1 RAs may benefit IIH management,” the authors write. “However, prospective studies are warranted to validate these findings.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n